Trial Profile
The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- 24 Jun 2016 New trial record